A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC

Completed

• Conditions: Pancreatic Ductal Adenocarcinoma

• Registration Number: NCT04726956
• Lead Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Brief Summary

The purpose of this study is to clarify the diagnostic significance of AKR1B10 in patients with pancreatic ductal adenocarcinoma, and to combine with CA19-9 to improve the diagnosis rate of pancreatic ductal adenocarcinoma.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-01-26
• Study First Submitted QC: 2021-01-26
• Study First Posted: 2021-01-27
• Study Start: 2021-02-01
• Primary Completion: 2021-12-31
• Study Completion: 2022-02-01
• Status Verified: 2022-07
• Last Update Submitted: 2024-10-14
• Last Update Posted: 2024-10-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 258

Inclusion Criteria

Not provided

Exclusion Criteria

1. PDAC group:

2. Patients who have undergone radiotherapy, chemotherapy and other tumor-related treatments before surgery;

3. Patients with non-primary pancreatic cancer;

4. Patients undergoing secondary operations;

5. Infected with HIV or AIDS related diseases;

6. Diagnosed as chronic or acute gastroenteritis;

7. Pregnant women;

8. Other situations that are not suitable for this research; 2. Benign group

(1) Patients who have undergone related surgical treatment in other hospitals; (2) Patients with a history of malignant tumors; 3. Healthy group:

1. Patients with a history of tumor;
2. Tumors found in medical examinations;
3. History of hepatitis B or C;
4. A history of acute or chronic gastroenteritis, cholecystitis, and cholangitis.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CA199 and AKR1B10 were detected in the sera of PDAC patients and Benign patients before surgery, as well as in the sera of healthy donors	1 week

Secondary Outcome Measures

Name	Time	Method
CA125, CEA, and AFP were detected in the sera of PDAC and Benign patients before surgery, as well as in the sera of healthy donors	1 week

Trial Locations

Locations (3)

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; 🇨🇳 Shanghai, Shanghai, China

Changhai Hospital of Shanghai; 🇨🇳 Shanghai, China

The First Affiliated Hospital of Zhengzhou University; 🇨🇳 Zhengzhou, China